Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease-Reference-Cited by-同舟云学术

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

Published:2002-07 Issue:1 Volume:30 Page:23-28
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Cohen AD,Luger SM,Sickles C,Mangan PA,Porter DL,Schuster SJ,Tsai DE,Nasta S,Gewirtz AM,Stadtmauer EA

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1703602.pdf

Reference33 articles.

1. Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia New Engl J Med 1999 341: 1051 1062

2. Webb D . Management of relapsed acute myeloid leukaemia Br J Haematol 1999 106: 851 859

3. Levy V, Marjanovic Z, Vekhoff A et al. Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years Am J Hematol 2000 64: 232 233

4. Dinndorf P, Andrews R, Benjamin D et al. Expression of normal myeloid–associated antigens by acute leukemia cells Blood 1986 67: 1048 1053

5. Sievers E, Appelbaum F, Speilberger R et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678 3684

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins;MacSween's Pathology of the Liver;2024

2. Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis;Hematology;2022-02-27

3. Stepping forward in antibody-drug conjugate development;Pharmacology & Therapeutics;2022-01

4. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults;Expert Opinion on Biological Therapy;2020-10-05

5. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors;International Journal of Cancer;2019-02-23